Skin and Soft Tissue Infections Market Size, Share & Report 2024-2031

Skin and Soft Tissue Infections Market Size, Share, Industry, Forecast and outlook (2024-2031)

<h2>Global Skin and Soft Tissue Infections Market is segmented By Drug Type (Antibiotics, Anti-fungal agents), By End User (Outpatient clinics, Emergency Department, Inpatient ward), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2024-2031</h2>

&nbsp;

<h3>Report&nbsp;Overview</h3>

<blockquote>
The Global Skin and Soft Tissue Infections Market are expected to grow at a high CAGR during the forecast&nbsp;period (2024-2031).&nbsp;
</blockquote>

<ul>
	<li>Skin and Soft Tissue Infections (SSTI) result from the microbial invasion of the surface and its supporting structures.</li>
	<li>They encompass a broad spectrum of inflammatory diseases of the skin, subcutis, fascia, and muscles.</li>
	<li>SSTIs are the second most common infection encountered in hospitals.</li>
	<li>SSTIs can lead to complications with significant morbidity, including hospitalization, surgical procedures, bacteremia, and even death.</li>
</ul>

<h3>Market Growth</h3>

<ul>
	<li>The global Skin and Soft Tissue Infections market is estimated to show significant growth.</li>
	<li>Major market drivers include&nbsp;raising some MRSA infections and new product developments.</li>
	<li>Resistance to new strains of infectious bacteria is the most critical factor affecting the SSTI drug market, in both community and hospital settings.</li>
</ul>

<h3>Market Segmentation</h3>

<ul>
	<li>Global Skin and Soft Tissue Infections market report segments the market by drug class, end-user, and by region.</li>
	<li>Based on the medications used for its treatment, the market includes antibiotics and anti-fungal agents.</li>
	<li>Antibiotics further include beta-lactam and macrolides.</li>
</ul>

<h3>Market Geographical Share</h3>

<ul>
	<li>The skin and soft tissue infections market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW.</li>
	<li>North America will dominate the market owing to high the incidence of infections.</li>
	<li>SSTIs account for more than 14 million physician office visits each year in the US, as well as emergency department visits and hospitalizations.</li>
</ul>

<h3>Market Scope of the report</h3>

The report also profiles the following companies of the Skin and Soft Tissue Infections market &ndash; Cubist Pharmaceuticals, Inc., Wockhardt Limited, Atox Bio Inc., Durata Therapeutics, Inc., Basilea Pharmaceutica AG, and Melinta Therapeutics Inc.

By Drug Type

<ul>
	<li>Antibiotics</li>
	<li>Anti-fungal agents</li>
</ul>

By End-User

<ul>
	<li>Outpatient clinics</li>
	<li>Emergency department</li>
	<li>Inpatient ward</li>
</ul>

By Region

<ul>
	<li>Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)</li>
	<li>Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)</li>
	<li>North America (The USA, Canada, Mexico)</li>
	<li>South America (Brazil, Argentina, Rest of South America)</li>
	<li>Rest of the World</li>
</ul>

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Scope of the Report

Chapter 2. Trends

2.1. Key Trends &amp; Developments

Chapter 3. Industry Analysis

3.1. Market Drivers

3.1.1. Rising number of MRSA infections

3.1.2. New product development

3.2. Market Restraints

3.2.1. Resistance to new strains of infectious bacteria

3.3. Threats and Opportunities

Chapter 4. Market Analysis

4.1. Skin and Soft Tissue Infections Market - By Drug Type

4.1.1. Antibiotics

4.1.2. Anti-fungal agents

4.2. Skin and Soft Tissue Infections Market - By End User

4.2.1. Outpatient clinics

4.2.2. Emergency department

4.2.3. Inpatient ward

Chapter 5.&nbsp;Geographical Analysis

5.1. North America

5.1.1. The USA

5.1.2. Canada

5.1.3. Mexico

5.2. Europe

5.2.1. Germany

5.2.2. France

5.2.3. The UK

5.2.4. Italy

5.2.5. Spain

5.2.6. Rest of Europe

5.3. Asia Pacific

5.3.1. China

5.3.2. Japan

5.3.3. India

5.3.4. Australia

5.3.5. Rest of Asia Pacific

5.4. South America

5.4.1. Brazil

5.4.2. Argentina

5.4.3. Rest of South America

5.5. Rest of the World

Chapter 6. Competitive Landscape

6.1. Market Share Analysis

6.2. Mergers and Acquisitions Analysis

6.3. New Product Launches

Chapter 7. Company Profiles

7.1. Cubist Pharmaceuticals, Inc.

7.2. Wockhardt Limited

7.3. Atox Bio Inc.

7.4. Durata Therapeutics, Inc.

7.5. Basilea Pharmaceutica AG

7.6. Melinta Therapeutics Inc.

Chapter 8. Appendix

8.1. Sources

8.2. List of Tables

8.3. Expert Panel Validation

8.4. Disclaimer

8.5. Contact Us

Skin and Soft Tissue Infections Market Size, Share, Industry, Forecast and outlook (2024-2031)

Skin Cancer Drugs Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 March 01

Starting from

Soft Tissue Repair Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 January 11

Starting from

Soft Tissue Sarcoma Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 March 26

Starting from

Ebola Virus Infection Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 April 12

Starting from

Hospital Infection Therapeutics Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 January 10

Starting from

Bacterial Infectious Diseases Therapeutics Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 January 19

Starting from